1-3 of 3
Chun-Yu Liu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract C041: Safety and pharmacokinetic results from a phase 1, multicenter, open-label study of [fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) in subjects with advanced HER2-positive breast cancer

Dwan-Ying Chang, Chia-Chi Lin, Tom Wei-Wu Chen, Ching-Hung Lin, Jih-Hsiang Lee, Ta-Chung Chao, Chun-Yu Liu, Issei Achiwa, Emi Kamiyama, Yasuyuki Okuda, Caleb Lee, Yee Chao
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): C041.
https://doi.org/10.1158/1535-7163.TARG-19-C041
Published: 01 December 2019
View article titled, Abstract C041: Safety and pharmacokinetic results from a phase 1, multicenter, open-label study of [fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) in subjects with advanced HER2-positive breast cancer
Journal Articles

Dovitinib Induces Apoptosis and Overcomes Sorafenib Resistance in Hepatocellular Carcinoma through SHP-1–Mediated Inhibition of STAT3

Wei-Tien Tai, Ann-Lii Cheng, Chung-Wai Shiau, Chun-Yu Liu, Ching-Huai Ko, Mai-Wei Lin, Pei-Jer Chen, Kuen-Feng Chen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (2): 452–463.
https://doi.org/10.1158/1535-7163.MCT-11-0412
Published: 08 February 2012
View article titled, Dovitinib Induces Apoptosis and Overcomes Sorafenib Resistance in Hepatocellular Carcinoma through SHP-1–Mediated Inhibition of STAT3
Open the PDF for Dovitinib Induces Apoptosis and Overcomes Sorafenib Resistance in Hepatocellular Carcinoma through SHP-1–Mediated Inhibition of STAT3 in another window
Journal Articles

Bortezomib Sensitizes HCC Cells to CS-1008, an Antihuman Death Receptor 5 Antibody, through the Inhibition of CIP2A

Kuen-Feng Chen, Hui-Chuan Yu, Chun-Yu Liu, Hui-Ju Chen, Yi-Ching Chen, Duen-Ren Hou, Pei-Jer Chen, Ann-Lii Cheng
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (5): 892–901.
https://doi.org/10.1158/1535-7163.MCT-10-0794
Published: 08 May 2011
View article titled, Bortezomib Sensitizes HCC Cells to CS-1008, an Antihuman Death Receptor 5 Antibody, through the Inhibition of CIP2A
Open the PDF for Bortezomib Sensitizes HCC Cells to CS-1008, an Antihuman Death Receptor 5 Antibody, through the Inhibition of CIP2A in another window